Samia M Omar1,2, Nabila A Maziad3, Nourhan M El-Tantawy1. 1. 1 Department of Pharmaceutics, Faculty of Pharmacy, Helwan University, Helwan, Egypt. 2. 2 Department of Pharmaceutics, Faculty of Pharmacy, Ahram Canadian University (ACU), Cairo, Egypt. 3. 3 Department of Polymer Chemistry, National Center for Radiation Research and Technology, Atomic Energy Authority, Cairo, Egypt.
Abstract
PURPOSE: Inhalable pulmonary delivery of isoniazid (INH) may improve the efficacy and reduce drug resistance. METHOD: INH-loaded chitosan microparticles (Cs-Mps-1-3) were prepared as an inhalable carrier for the previously prepared INH-loaded polyvinylpyrrolidone/polyitaconic acid nanoparticles (NPs) using spray-drying technique. Here, Cs-Mps-1-3 are composed of Cs: INH-loaded NPs: Free INH at w/w ratios (1:1:0), (1: 0:1), and (1:1:1), respectively. Subsequently, the prepared Cs-Mps-1-3 characterizations were studied. RESULTS: Cs-Mps-1-3 showed a spherical, smooth, positively charged surface (ζ-potential values +20.2, +28.7, and +22.6) and a size range 1.52-3.12 μm. In addition, Carr's compressibility indices of Cs-Mps-1-3 were 32.5%, 24.8%, and 28.02%, respectively. The in vitro INH released showed good correlation with first-order pattern, with predominance of the diffusion-controlled mechanism. In vitro aerodynamic deposition of Cs-MPs-3 possessed 56.81% effective fine particle fraction with lower impaction loss and device retention (10.47% and 30.9% at mouth and throat and at stage 1, respectively). The minimum inhibitory concentration of Cs-Mps-3 displayed 63-fold more inhibition effects on Mycobacterium tuberculosis than INH solution, owing to the combined effect of positively charged Cs-Mps with their facilitating bacterial cell surface binding and cellular penetration activity of NPs. CONCLUSION: The promising potential of Cs-Mps-3 as an inhalable carrier for pulmonary delivery of INH is recommended.
PURPOSE: Inhalable pulmonary delivery of isoniazid (INH) may improve the efficacy and reduce drug resistance. METHOD: INH-loaded chitosan microparticles (Cs-Mps-1-3) were prepared as an inhalable carrier for the previously prepared INH-loaded polyvinylpyrrolidone/polyitaconic acid nanoparticles (NPs) using spray-drying technique. Here, Cs-Mps-1-3 are composed of Cs: INH-loaded NPs: Free INH at w/w ratios (1:1:0), (1: 0:1), and (1:1:1), respectively. Subsequently, the prepared Cs-Mps-1-3 characterizations were studied. RESULTS:Cs-Mps-1-3 showed a spherical, smooth, positively charged surface (ζ-potential values +20.2, +28.7, and +22.6) and a size range 1.52-3.12 μm. In addition, Carr's compressibility indices of Cs-Mps-1-3 were 32.5%, 24.8%, and 28.02%, respectively. The in vitro INH released showed good correlation with first-order pattern, with predominance of the diffusion-controlled mechanism. In vitro aerodynamic deposition of Cs-MPs-3 possessed 56.81% effective fine particle fraction with lower impaction loss and device retention (10.47% and 30.9% at mouth and throat and at stage 1, respectively). The minimum inhibitory concentration of Cs-Mps-3 displayed 63-fold more inhibition effects on Mycobacterium tuberculosis than INH solution, owing to the combined effect of positively charged Cs-Mps with their facilitating bacterial cell surface binding and cellular penetration activity of NPs. CONCLUSION: The promising potential of Cs-Mps-3 as an inhalable carrier for pulmonary delivery of INH is recommended.